- Home
- KNSA vs FORM Comparison
KNSA vs FORM Comparison
Compare KNSA & FORM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KNSA
- FORM
- Stock Information
- Founded
- KNSA 2015
- FORM 1993
- Country
- KNSA United Kingdom
- FORM United States
- Employees
- KNSA N/A
- FORM N/A
- Industry
- KNSA Biotechnology: Pharmaceutical Preparations
- FORM Semiconductors
- Sector
- KNSA Health Care
- FORM Technology
- Exchange
- KNSA Nasdaq
- FORM Nasdaq
- Market Cap
- KNSA 2.1B
- FORM 2.2B
- IPO Year
- KNSA 2018
- FORM N/A
- Fundamental
- Price
- KNSA $27.53
- FORM $34.42
- Analyst Decision
- KNSA Strong Buy
- FORM Buy
- Analyst Count
- KNSA 5
- FORM 7
- Target Price
- KNSA $38.80
- FORM $41.17
- AVG Volume (30 Days)
- KNSA 1.1M
- FORM 687.5K
- Earning Date
- KNSA 07-22-2025
- FORM 07-30-2025
- Dividend Yield
- KNSA N/A
- FORM N/A
- EPS Growth
- KNSA N/A
- FORM N/A
- EPS
- KNSA N/A
- FORM 0.69
- Revenue
- KNSA $481,166,000.00
- FORM $766,230,000.00
- Revenue This Year
- KNSA $37.21
- FORM $2.18
- Revenue Next Year
- KNSA $5.32
- FORM $7.14
- P/E Ratio
- KNSA N/A
- FORM $49.93
- Revenue Growth
- KNSA 59.45
- FORM 15.33
- 52 Week Low
- KNSA $17.38
- FORM $22.58
- 52 Week High
- KNSA $30.69
- FORM $63.63
- Technical
- Relative Strength Index (RSI)
- KNSA 54.29
- FORM 62.41
- Support Level
- KNSA $27.62
- FORM $31.91
- Resistance Level
- KNSA $29.23
- FORM $35.02
- Average True Range (ATR)
- KNSA 1.03
- FORM 1.16
- MACD
- KNSA -0.21
- FORM 0.02
- Stochastic Oscillator
- KNSA 46.99
- FORM 84.38
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
About FORM FormFactor Inc. FormFactor Inc.
FormFactor Inc is a provider of electrical and optical test and measurement technologies along the full semiconductor product lifecycle - from characterization, modeling, reliability, and design de-bug, to qualification and production test.. The company operates in two reportable segments namely Probe Cards Segment and the Systems Segment. Sales of probe cards and analytical probes are included in the Probe Cards Segment, while sales of probe stations and thermal sub-systems are included in the Systems Segment. Probe cards generate the maximum revenue from its operations. It offers multiple product lines which include analytical probes, probe stations, thermal sub-systems, and related services.